Yazan: admin Tarih: Tem 23rd, 2010 | Kategori::
Prostate cancer(Prostat Kanseri)
Cancer Invest. 2006 Feb;24(1):41-5.
Silig Y, Pinarbasi H, Günes S, Ayan S, Bagci H, Cetinkaya O.
Cumhuriyet University, Science and Art Faculty, Department of Biochemistry, Sivas, Turkey. ysilig@cumhuriyet.edu.tr
Abstract
Prostate cancer is the most common cancer among men in many countries. Although the etiology of prostate cancer largely is unknown, both genetic and environmental factors may be involved. Advanced age, androgen metabolism, and heredity-race have been reported to be possible risk factors. On the other hand, several studies indicate that genetic polymorphisms in biotransformation enzymes play a role in prostate cancer development. In this study, association of the prostate cancer risk with genotype frequencies of the Phase I (CYP1A1) and Phase II (GSTM1 and GSTT1) biotransformation enzymes was investigated in 321 Turkish individuals (152 prostate cancer patients and 169 age-matched male controls). The presence or absences of the GSTM1 and GSTT1 genes were determined by a PCR-based method. Genotypes of CYP1A1 were determined by MspI-RFLP. The prevalence of GSTM1 null genotype in the cases was 64 percent, compared to 31 percent in the control group, indicating a strong association (OR = 4.08, 95%CI = 2.50-6.69). No association was observed between either GSTT1 null genotype or CYP1A1 polymorphism and prostate cancer incidence. No statistically significant association was observed between smoking status of the patients and any of the polymorphisms studied. In conclusion, results of this study indicate that only the GSTM1 null genotype may play an important role as a risk factor for prostate cancer development in Turkish population.
Yazan: admin Tarih: Ağu 10th, 2008 | Kategori::
Prostate cancer(Prostat Kanseri)
Res Commun Mol Pathol Pharmacol. 2003;113-114:307-14. Links
Department of Basic Oncology, Istanbul University, Oncology Institute 34390 Capa, Istanbul, Turkey.
Steroid hormones, especially androgens, are believed to play a key role in the etiology of prostate cancer. Therefore, polymorphisms in genes involved in the androgen metabolism may affect the risk of prostate cancer. One such gene is CYP17, which encodes the cytochrome P450c17alpha enzyme that mediates both 17alpha-hydroxylase and 17,20-lyase in the steroid biosynthesis pathway. A polymorphism in the 5′-promoter region of the CYP17 gene has been associated with increased risk for prostate cancer. The T to C transition in the risk allele creates a new recognition site for the restriction enzyme MspA1. In this study we investigated the distribution of this polymorphism in the Turkish population and its association with prostate cancer and benign prostatic hyperplasia. Genotype frequencies in the patients with prostate cancer or prostatic hyperplasia and the control group were not significantly different. Our data provide no evidence for an association between prostate cancer risk and the CYP17 gene polymorphism.
Yazan: admin Tarih: Ağu 4th, 2008 | Kategori::
GSTM1,
GSTT1,
Prostate cancer(Prostat Kanseri)
-
-
Cumhuriyet University, Science and Art Faculty, Department of Biochemistry, Sivas, Turkey. ysilig@cumhuriyet.edu.tr
Prostate cancer is the most common cancer among men in many countries. Although the etiology of prostate cancer largely is unknown, both genetic and environmental factors may be involved. Advanced age, androgen metabolism, and heredity-race have been reported to be possible risk factors. On the other hand, several studies indicate that genetic polymorphisms in biotransformation enzymes play a role in prostate cancer development. In this study, association of the prostate cancer risk with genotype frequencies of the Phase I (CYP1A1) and Phase II (GSTM1 and GSTT1) biotransformation enzymes was investigated in 321 Turkish individuals (152 prostate cancer patients and 169 age-matched male controls). The presence or absences of the GSTM1 and GSTT1 genes were determined by a PCR-based method. Genotypes of CYP1A1 were determined by MspI-RFLP. The prevalence of GSTM1 null genotype in the cases was 64 percent, compared to 31 percent in the control group, indicating a strong association (OR = 4.08, 95%CI = 2.50-6.69). No association was observed between either GSTT1 null genotype or CYP1A1 polymorphism and prostate cancer incidence. No statistically significant association was observed between smoking status of the patients and any of the polymorphisms studied. In conclusion, results of this study indicate that only the GSTM1 null genotype may play an important role as a risk factor for prostate cancer development in Turkish population.
